



We want to save patients with severe cancer and autoimmune diseases  
*Clinical investigations with our lead antibody CAN04 to our proprietary target*

Göran Forsberg, CEO

# Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are well-considered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.

# Cantargia

- Specialized in antibody therapy/immunology/oncology
- Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020
- Platform around IL1RAP, lead candidate for autoimmunity and inflammatory disease 2019
- Granted IP - therapeutic target IL1RAP and CAN04
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- More than 5000 shareholders incl strong long term investors
- Based in Lund, Sweden

## Financial highlights


- Share price: 17.02 SEK (1.77 USD), Aug 23, 2019
- Market cap: 1239 MSEK (129 MUSD), Aug 23, 2019
- Cash: 219 MSEK (22.8 MUSD), Jun 30, 2019

## Current owners (June 30, 2019)


Sunstone	8.2%
Alecta	6.6%
1st AP fund	6.3%
4th AP fund	5.9%
Avanza Pension	5.8%
Öhman Bank S.A.	4.2%
2nd AP fund	3.0%
SEB S.A.	2.8%
Handelsbanken fonder	1.9%
Mats Invest AB	1.8%
Others	53.6%

# Cantargia – opportunity to save lives and create value

- Potentially more effective treatment against novel target in clinically validated pathway
- Right team and clear plan to position our projects and maximize value
- First in class platform technology against novel target



# Cantargia core – tumor inflammation



Cancer caused by two enablers:


- Genomic instability/mutations
- Inflammation

**Counteracting inflammation - strategy for novel therapies**

# Validating study – counteracting tumor inflammation

## CANTOS trial (n=10061)

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67 % and death by 77 %.



- Clinical validation of IL-1 pathway
- Dose/response
- Cantargia's CAN04 has broader MOA

**Canakinumab phase 3 trials** (compl 20121/2022)

**Adjuvant NSCLC (CANOPY-A)** 1500 patients  
After surgery, no mets, placebo control

**First line (CANOPY-1)** 627 patients  
Untreated locally advanced/metastatic  
Combination Pembro/Platinum doublet



**Second line metastatic (CANOPY-2)** 240 patients  
Previously treated loc adv/metastatic  
Combination Docetaxel

...and additional trials in:

- Renal cell cancer
- Gastroesophageal cancer
- Colorectal cancer
- NSCLC

Source [clinicaltrials.gov](https://clinicaltrials.gov)

# CAN04 (nidanilimab) added value vs canakinumab




## Canakinumab

- Antibody directed against one of the two IL-1 ligands, IL-1β

## CAN04:

### Double mechanism

- Binds the signaling receptor and counteracts both ligands
- Induce killing via the immune system (ADCC)



..Cantargia has patents on IL1RAP


CAN04 has a strong potential to treat cancer



# CAN04 – CANFOUR clinical trial

## Phase I/IIa trial - NSCLC and pancreatic cancer

- Phase I data presented orally at ASCO 2019
- 22 patients (NSCLC, pancreatic cancer, colon cancer)
  - Good safety up to 10 mg/kg
  - Significant effect on relevant biomarkers (IL-6, CRP)
  - 9 pts had stable disease up to 6 months
- Phase IIa: (appr 20 centres)
  - FPI Jan 2019 –Data early 2020
  - Monotherapy (20 pat) fully recruited, 15 mg/kg to start
  - Combination with standard therapy (appr 30 pat per arm)
    - NSCLC Cisplatin/Gemcitabine
    - Pancreatic cancer Gemcitabine/nab-paclitaxel
- ..and new complementary trial to open in USA




Details on [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Generation of data instrumental for next phase of development



# IL1RAP in several cancer with high medical need




- Cantargia founded based on:
  - Discovery of IL1RAP on cancer cells
  - Antibodies against IL1RAP - antitumor effects
  - IP on antibody therapy against IL1RAP
- Primary indications. NSCLC and pancreatic cancer
- Biomarker studies ongoing, identify patients most likely to respond
- Opportunity to expand development in additional cancer forms
- Cantargia has granted patents on antibody therapy against IL1RAP

CAN04 development can be expanded to additional indications in the future

9

# CAN04 attacks several cell types in the tumor




**CAN04 is relevant to several parts of cancer progression**

# Two major preclinical findings during 2018

## -new opportunities

### **Synergistic effects with chemotherapy**


- Stronger antitumor effects
- Counteracts chemotherapy toxicity



### **Binding to immune cells in tumor microenvironment**

- Antimetastatic effects
- Counteract immune suppression


# Targeting IL1RAP allows synergistic effects with Cisplatin/Gemcitabine



- CAN04 increases antitumor effects of platinum compounds (cisplatin, carboplatin, oxaliplatin)
- CAN04 counteracts toxicity from platinum compounds

# IL1RAP platform to treat serious diseases

- Three different systems signal through IL1RAP
- These systems contribute to various inflammatory diseases
- Can be blocked by Cantargia's antibodies against IL1RAP



Cantargia partnership with Panorama Res Inc (Sunnyvale, CA)  
Selection of clinical candidate 2019 in CANxx project

# Significant value inflection points ahead of CANFOUR results

## 2019

- US regulatory and clinical strategy
- Phase IIa monotherapy results
- Clinical progress and initial phase IIa results
- Preclinical progress (immuno-oncology effects, combinations etc)
- CANxx progress
- US clinical trial

## 2020

- Phase IIa combination results
- Phase IIa expansion

**Significant data to secure newsflow 2019-2020**

# Cantargia

- Specialized in antibody therapy/immunology/oncology
- Lead antibody CAN04 (nidanilimab) in phase IIa clinical development, pathway clinically validated, data early 2020
- Platform around IL1RAP, lead candidate for autoimmunity and inflammatory disease 2019
- Granted IP - therapeutic target IL1RAP and CAN04
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- More than 5000 shareholders incl strong long term investors
- Based in Lund, Sweden

## Financial highlights

- Share price: 17.02 SEK (1.77 USD), Aug 23, 2019
- Market cap: 1239 MSEK (129 MUSD), Aug 23, 2019
- Cash: 219 MSEK (22.8 MUSD), Jun 30, 2019

## Current owners (June 30, 2019)

Sunstone	8.2%
Alecta	6.6%
1st AP fund	6.3%
4th AP fund	5.9%
Avanza Pension	5.8%
Öhman Bank S.A.	4.2%
2nd AP fund	3.0%
SEB S.A.	2.8%
Handelsbanken fonder	1.9%
Mats Invest AB	1.8%
Others	53.6%